ADAR1 Capital Management, the largest stockholder of Keros Therapeutics (KROS) with approximately 13.3% of the Company’s outstanding shares, released an investor presentation outlining its rationale for withholding votes on the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the Keros Board of Directors at the Company’s upcoming Annual Meeting of Stockholders, scheduled for June 4, 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics price target lowered to $26 from $41 at Scotiabank
- Keros Therapeutics CEO to Speak at Healthcare Conference
- Keros Therapeutics price target lowered to $25 from $40 at H.C. Wainwright
- Keros Therapeutics: Buy Rating Affirmed Amid Promising Trial Data and Strategic Initiatives
- Keros Therapeutics Reports Strong Q1 2025 Results